Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
MYGN Myriad Genetics
Post Mkt Price
Do not show
Hide blank lines
Total revenue
-4.74% 164.9M 130.35% 690.6M 160.8M 167.3M
Operating revenue
-4.74% 164.9M 130.35% 690.6M -- 160.8M -- 167.3M
Cost of revenue
-4.57% 48M 116.19% 197.6M 45.8M 47.8M
Gross profit
-4.8% 116.9M 136.56% 493M 115M 119.5M
Operating expense
-21.83% 131.8M 132.9% 681.7M 158.1M 199M
Selling and administrative expenses
-23.99% 110.6M 133.48% 599.8M -- 141.5M -- 180.2M
-General and administrative expense
-- -- -- 599.8M -- 141.5M -- --
Research and development costs
-8.23% 21.2M 128.77% 81.9M -- 16.6M -- 18.8M
Operating profit
67.47% -14.9M -123.84% -188.7M -43.1M -79.5M
Net non-operating interest income expense
71.43% -800K -15.69% -5.9M -300K -900K
Non-operating interest income
-50% 100K 0% 700K -- 200K -- 200K
Non-operating interest expense
-70% 900K 13.79% 6.6M -- 500K -- 1.1M
Other net income (expense)
-970% -10.7M 3025.53% 137.5M -100K 120.2M
Special income (charges)
-1088.89% -10.7M 48.57% -1.8M -- 0 -- -400K
-Less:Restructuring and merger&acquisition
-- -- -- -- -- -- -- 400K
-Less:Impairment of capital assets
-- 10.7M -- 1.8M -- 0 -- 0
Other non- operating income (expenses)
-- -- 11708.33% 139.3M -- -100K -- 120.6M
Income before tax
46.77% -26.4M 39.32% -57.1M -43.5M 39.8M
Income tax
41.58% -5.9M 27.07% -29.9M -35.9M 15.2M
Net income
48.1% -20.5M 48.78% -27.2M -7.6M 24.6M
Net income continuous Operations
48.1% -20.5M 48.78% -27.2M -- -7.6M -- 24.6M
Minority interest income
0 0 0 0
Net income attributable to the parent company
48.1% -20.5M 48.78% -27.2M -7.6M 24.6M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
48.1% -20.5M 48.78% -27.2M -7.6M 24.6M
Basic earnings per share
50% -0.26 50.7% -0.35 -0.1 0.31
Diluted earnings per share
50% -0.26 50.7% -0.35 -0.1 0.3
Dividend per share
Currency Unit
Accounting Standards
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
CEO: Diaz, Paul J.
Market: NASDAQ
Hot List
SymbolLatest price%Chg